Russia transfers technology to produce insulin pens to treat diabetes to Vietnam

Insulin injection pens for diabetes treatment and many other advanced biological drugs for prevention and treatment of vascular diseases, viral diseases, infertility, etc. will have their production technology transferred to Vietnam by Russia.

On the evening of September 12, VNVC Vaccine and Biological Factory and Medsintez Pharmaceutical Company (Russian Federation) signed a cooperation agreement on technology transfer for comprehensive production of new generation biological drugs, serving the treatment of many dangerous acute and chronic diseases with Medsintez Company (Russian Federation).

The signing ceremony took place under the witness of Russian Minister of Health Mikhail Murashko and Vietnamese Minister of Health Dao Hong Lan.

Mr. Konstantin Gorodnitsky, Head of Medsintez Company Representative Office in Vietnam and Ms. Tran Thi Hong Thuy, Director of VNVC Vaccine and Biological Factory signed the cooperation agreement under the witness of Russian Minister of Health Mikhail Murashko and Vietnamese Minister of Health Dao Hong Lan. Photo: Pham Giang.

Speaking at the event, Russian Minister of Health Mikhail Murashko said: “I believe that the cooperation between Vietnam and Russia in the health sector is a path of innovation and mutual benefit, aiming at the highest goal of protecting people's health and improving the quality of the health sector.”

Minister Dao Hong Lan, on behalf of the Ministry of Health and the people of Vietnam, thanked the Russian Government and Ministry of Health for their support over the past decades in training doctors, providing medicines, vaccines, modern techniques and building medical facilities. Minister Dao Hong Lan expressed her joy at witnessing the cooperation between research institutes, high-tech medical centers and prestigious medical units of the two countries, which will open up many practical cooperation programs, especially in cancer treatment with advanced technology as well as the production of medicines, vaccines and medical biological products - which are urgent needs not only of Vietnam, Russia but also of the world.

Previously, in May 2025 in Moscow, under the witness of General Secretary To Lam and Russian President Putin, the two ministers signed a cooperation agreement and witnessed VNVC signing a comprehensive cooperation agreement with the Russian Direct Investment Fund (RDIF) - the highest representative of Russian pharmaceutical research and production agencies as well as other health agencies.

VNVC Vaccine Company and the Russian Direct Investment Fund (RDIF) exchanged cooperation documents in the presence of General Secretary To Lam and Russian President Putin (May 2025). Photo: Hoang Thong Nhat.

And after only 5 months, VNVC has reached a comprehensive technology transfer agreement with Medsintez - a large Russian pharmaceutical company, to soon bring to Vietnam to produce the world's leading advanced biological drugs from Russia for the treatment of diabetes, obesity, vascular diseases, viral diseases, especially dengue fever.

Immediately after signing, Medsintez and VNVC will carry out steps to transfer Medsintez's advanced biological drug production technology at VNVC Vaccine and Biological Factory, cooperate in research and development and clinical research of new drugs and vaccines, and distribute Medsintez's high-quality pharmaceutical products in Vietnam and ASEAN countries.

It is expected that in the near future, many advanced biological drug categories of Medsintez will be transferred for comprehensive production at VNVC Vaccine and Biological Factory with high international standards, such as Recombinant Albumin, Recombinant Insulin, disposable and reusable Insulin pens, diabetes treatment drugs (liraglutide, semaglutide), anticoagulant Heparin (prevention and treatment of thrombotic complications causing blood vessel blockage leading to stroke, myocardial infarction, pulmonary embolism), antiviral drug Triazavirin, follicle stimulating hormone (used in infertility treatment)...

In particular, the two sides will discuss the coordination of clinical research on the antiviral drug Triazavirin in the treatment of dengue fever, a disease that causes hundreds of thousands of cases and dozens of deaths each year in Vietnam. Triazavirin is a drug recommended by the Ministry of Health of the Russian Federation for both the prevention and treatment of COVID-19, and is also considered to have the potential to expand the treatment of viral diseases.

VNVC has a system of nearly 240 vaccination centers across the country, serving tens of millions of doses of high-quality vaccines, protecting the health of children and adults over the past nearly 10 years. Photo: Moc Thao.

Mr. Ngo Chi Dung, Chairman of the Board of Directors and General Director of VNVC Vaccine and Biological Factory, said that cooperation with Medsintez is one of many in-depth cooperation agreements that VNVC and its ecosystem members, the Research Institute and Tam Anh General Hospital System, will sign with research institutes, hospitals and major Russian pharmaceutical companies.

“These cooperations are in line with our goal of expanding our extensive international cooperation with major medical centers around the world to gain early access to new drugs, vaccines, and medical examination and treatment technologies, serving Vietnamese people and international tourists seeking medical treatment in Vietnam,” said Mr. Ngo Chi Dung.

VNVC Vaccine and Biological Factory located in Tay Ninh applies international GMP standards of WHO, EU (Europe), FDA (USA), with a total initial investment capital of more than 2,000 billion VND, expected to start producing new generation vaccines and advanced biological drugs of many countries around the world right in Vietnam by the end of 2027.

The event of VNVC signing with Medsintez opens up opportunities for Vietnam to access early sources of high-quality biological drugs in the treatment of infectious diseases and dangerous chronic diseases, gradually shortening the roadmap for mastering technology, reducing import costs, moving towards self-sufficiency in domestic supply and moving towards export, thereby affirming its position as a prestigious center for production and supply of vaccines and biological products in the ASEAN region.

Source: https://cand.com.vn/y-te/nga-chuyen-giao-cong-nghe-san-xuat-but-tiem-insulin-tri-tieu-duong-cho-viet-nam-i781239/